Cargando…
Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias – assessment of clinical outcome, post induction, end of treatment and minimal residual disease
INTRODUCTION: The extracellular matrix protein hyaluronan acid plays an active in role in tumor cell proliferation and invasion. Hyaluronan acid receptors, namely CD168 or the receptor for hyaluronan acid-mediated motility (RHAMM) and CD44 have been implicated in promoting malignancy. There is a lac...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200675/ https://www.ncbi.nlm.nih.gov/pubmed/30370408 http://dx.doi.org/10.1016/j.htct.2018.01.008 |
_version_ | 1783365367070982144 |
---|---|
author | Shalini, Chinnathambi Narayanan Sai Suman, Febe Renjitha Jacob, Jerusha Samuela Rajendran, Rithika Scott, Julius Xavier Latha, Magadha Sneha |
author_facet | Shalini, Chinnathambi Narayanan Sai Suman, Febe Renjitha Jacob, Jerusha Samuela Rajendran, Rithika Scott, Julius Xavier Latha, Magadha Sneha |
author_sort | Shalini, Chinnathambi Narayanan Sai |
collection | PubMed |
description | INTRODUCTION: The extracellular matrix protein hyaluronan acid plays an active in role in tumor cell proliferation and invasion. Hyaluronan acid receptors, namely CD168 or the receptor for hyaluronan acid-mediated motility (RHAMM) and CD44 have been implicated in promoting malignancy. There is a lacuna in data on the expression of the receptor in pediatric leukemias. METHODS: Pediatric patients with acute leukemia who were diagnosed, treated and followed up in our center were enrolled. The bone marrow biopsies performed prior to treatment were subjected to immunohistochemical staining (54 biopsies: acute lymphoblastic leukemia – 45, acute myeloid leukemia – 9). Blast counts were carried out at diagnosis, end of the induction phase and end of chemotherapy, the minimal residual disease was assessed and follow up details were collected. Positivity was correlated with initial blast count, post-induction blast count, minimal residual disease and patient survival. RESULTS: There was no correlation between the initial blast count and the percentage of blasts with RHAMM expression. The positive correlation between percentage of blasts expressing RHAMM and the post-induction blast count was moderate in acute myeloid leukemia (0.74) and mild in acute lymphoblastic leukemia (0.48). There was a statistically significant difference in RHAMM expression between the two minimal residual disease risk groups (p-value = 0.012) with a negative prognostic effect of RHAMM expression. Moreover, a negative prognostic effect of RHAMM expression was noted when patient survival was considered. CONCLUSION: This study shows that blasts in acute myeloid leukemia show more RHAMM positivity than those of acute lymphoblastic leukemia indicating the aggressive nature of this type of leukemia. In acute leukemias, patients with high percentages of RHAMM-positive blasts had more post-induction blasts, blasts in minimal residual disease and poorer prognosis. |
format | Online Article Text |
id | pubmed-6200675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Sociedade Brasileira de Hematologia e Hemoterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-62006752018-10-26 Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias – assessment of clinical outcome, post induction, end of treatment and minimal residual disease Shalini, Chinnathambi Narayanan Sai Suman, Febe Renjitha Jacob, Jerusha Samuela Rajendran, Rithika Scott, Julius Xavier Latha, Magadha Sneha Hematol Transfus Cell Ther Original Article INTRODUCTION: The extracellular matrix protein hyaluronan acid plays an active in role in tumor cell proliferation and invasion. Hyaluronan acid receptors, namely CD168 or the receptor for hyaluronan acid-mediated motility (RHAMM) and CD44 have been implicated in promoting malignancy. There is a lacuna in data on the expression of the receptor in pediatric leukemias. METHODS: Pediatric patients with acute leukemia who were diagnosed, treated and followed up in our center were enrolled. The bone marrow biopsies performed prior to treatment were subjected to immunohistochemical staining (54 biopsies: acute lymphoblastic leukemia – 45, acute myeloid leukemia – 9). Blast counts were carried out at diagnosis, end of the induction phase and end of chemotherapy, the minimal residual disease was assessed and follow up details were collected. Positivity was correlated with initial blast count, post-induction blast count, minimal residual disease and patient survival. RESULTS: There was no correlation between the initial blast count and the percentage of blasts with RHAMM expression. The positive correlation between percentage of blasts expressing RHAMM and the post-induction blast count was moderate in acute myeloid leukemia (0.74) and mild in acute lymphoblastic leukemia (0.48). There was a statistically significant difference in RHAMM expression between the two minimal residual disease risk groups (p-value = 0.012) with a negative prognostic effect of RHAMM expression. Moreover, a negative prognostic effect of RHAMM expression was noted when patient survival was considered. CONCLUSION: This study shows that blasts in acute myeloid leukemia show more RHAMM positivity than those of acute lymphoblastic leukemia indicating the aggressive nature of this type of leukemia. In acute leukemias, patients with high percentages of RHAMM-positive blasts had more post-induction blasts, blasts in minimal residual disease and poorer prognosis. Sociedade Brasileira de Hematologia e Hemoterapia 2018 2018-04-18 /pmc/articles/PMC6200675/ /pubmed/30370408 http://dx.doi.org/10.1016/j.htct.2018.01.008 Text en © 2018 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Shalini, Chinnathambi Narayanan Sai Suman, Febe Renjitha Jacob, Jerusha Samuela Rajendran, Rithika Scott, Julius Xavier Latha, Magadha Sneha Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias – assessment of clinical outcome, post induction, end of treatment and minimal residual disease |
title | Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias – assessment of clinical outcome, post induction, end of treatment and minimal residual disease |
title_full | Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias – assessment of clinical outcome, post induction, end of treatment and minimal residual disease |
title_fullStr | Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias – assessment of clinical outcome, post induction, end of treatment and minimal residual disease |
title_full_unstemmed | Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias – assessment of clinical outcome, post induction, end of treatment and minimal residual disease |
title_short | Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias – assessment of clinical outcome, post induction, end of treatment and minimal residual disease |
title_sort | prognostic significance of receptor for hyaluronan acid-mediated motility (cd168) in acute pediatric leukemias – assessment of clinical outcome, post induction, end of treatment and minimal residual disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200675/ https://www.ncbi.nlm.nih.gov/pubmed/30370408 http://dx.doi.org/10.1016/j.htct.2018.01.008 |
work_keys_str_mv | AT shalinichinnathambinarayanansai prognosticsignificanceofreceptorforhyaluronanacidmediatedmotilitycd168inacutepediatricleukemiasassessmentofclinicaloutcomepostinductionendoftreatmentandminimalresidualdisease AT sumanfeberenjitha prognosticsignificanceofreceptorforhyaluronanacidmediatedmotilitycd168inacutepediatricleukemiasassessmentofclinicaloutcomepostinductionendoftreatmentandminimalresidualdisease AT jacobjerushasamuela prognosticsignificanceofreceptorforhyaluronanacidmediatedmotilitycd168inacutepediatricleukemiasassessmentofclinicaloutcomepostinductionendoftreatmentandminimalresidualdisease AT rajendranrithika prognosticsignificanceofreceptorforhyaluronanacidmediatedmotilitycd168inacutepediatricleukemiasassessmentofclinicaloutcomepostinductionendoftreatmentandminimalresidualdisease AT scottjuliusxavier prognosticsignificanceofreceptorforhyaluronanacidmediatedmotilitycd168inacutepediatricleukemiasassessmentofclinicaloutcomepostinductionendoftreatmentandminimalresidualdisease AT lathamagadhasneha prognosticsignificanceofreceptorforhyaluronanacidmediatedmotilitycd168inacutepediatricleukemiasassessmentofclinicaloutcomepostinductionendoftreatmentandminimalresidualdisease |